
Defining the Next Era of Cancer Therapeutics
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...
Continue Reading
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...
Continue Reading
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an exceptional group of regional industry leaders...
Continue Reading
Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...
Continue Reading
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
Continue Reading
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....
Continue Reading
Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...
Continue ReadingAntibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...
Continue Reading
Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...
Continue Reading
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading